



ASX RELEASE (15 DECEMBER 2020)

THC Global to Benefit from TGA Down-Scheduling of CBD

Key Points:

- **THC Global supportive of TGA decision today to down-schedule low dose cannabidiol (CBD) medicines**
- **Low dose CBD to become available over the counter as S3 medicines once ARTG registered**
- **Southport Facility in position to be a market leader in high volume low dose CBD medicines production**

THC Global Group Limited (**THC Global** or the **Company**) is pleased with the Australian Therapeutic Goods Administration (TGA) announcing today that low dose cannabidiol (CBD) medicines will be down-scheduled to Schedule 3 enabling sale of these medicines over the counter.

With one of the world's largest cannabis extraction facilities, THC Global is well positioned to take advantage of this move towards over the counter CBD medicines sales with the capacity to commence high volume production in the near term. The TGA's final decision additionally increases the maximum recommended daily dosage to 150mg of cannabidiol compared to the 60mg in the previous proposal. The Company is of the view that this increased recommended daily dose will result in better potential patient outcomes.

The Company is continuing discussions with a number of parties as to the potential to commence the process of ARTG registration of a new low dose CBD medicine with the intention of launching as an over the counter S3 medicine through 2021. This final decision from the TGA will enable these discussions to accelerate with a view to commencement of production in the near term.

For further information, please contact:



THC GLOBAL GROUP

Jarrold White
Group Chief Executive Officer
e: ceo@thc.global

Sonny Didugu
Group Chief Operating Officer
e: coo@thc.global

Philip Leighfield
Joint Company Secretary
e: corporate@thc.global

ASX release authorised by THC Global's Management Committee.

THC Global Group Limited (ASX: THC) to be renamed Epsilon Healthcare Limited

THC Global is a diversified global healthcare and pharmaceuticals company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia's cannabis regulations. THC Global's Southport Facility in Southport, Australia is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates a fast growing turnkey cultivation solutions provider, including a hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sectors in North America and Europe.

